Skip to main content
SpringerLink
Log in

The in vitro and in vivo efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a murine vulvovaginitis model

  • Published:
Journal of Microbiology Aims and scope Submit manuscript

Abstract

Farnesol is a quorum-sensing molecule that inhibits biofilm formation in Candida albicans. Previous in vitro data suggest that, in combination with certain antifungals, farnesol may have an adjuvant anti-biofilm agent. However, the in vivo efficacy of farnesol is very questionable. Therefore, the in vitro and in vivo activity of fluconazole combined with farnesol was evaluated against C. albicans biofilms using fractional inhibitory concentration index (FICI) determination, time-kill experiments and a murine vulvovaginitis model. The median biofilm MICs of fluconazole-sensitive C. albicans isolates ranged between 4 -> 512 mg/L and 150–300 μM for fluconazole and farnesol, respectively. These values were 512 -> 512 mg/L and > 300 μM for fluconazole-resistant clinical isolates. Farnesol decreased the median MICs of fluconazole by 2-64-fold for biofilms. Based on FICI, synergistic interaction was observed only in the case of the sessile SC5314 reference strain (FICIs: 0.16–0.27). In time-kill studies, only the 512 mg/L fluconazole and 512 mg/L fluconazole + 75 μM farnesol reduced biofilm mass significantly at each time point in the case of all isolates. The combination reduced the metabolic activity of biofilms for all isolates in a concentration- and time-dependent manner. Our findings revealed that farnesol alone was not protective in a murine vulvovaginitis model. Farnesol was not beneficial in combination with fluconazole for fluconazole-susceptible isolates, but partially increased fluconazole activity against one fluconazole-resistant isolate, but not the other one.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 3rd ed. M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA, USA.

    Google Scholar 

  • Cordeiro, R.A., Teixeira, C.E., Brilhante, R.S., Castelo-Branco, D.S., Paiva, M.A., Giffoni Leite, J.J., Lima, D.T., Monteiro, A.J., Sidrim, J.J., and Rocha, M.F. 2013. Minimum inhibitory concentrations of amphotericin B, azoles and caspofungin against Candida species are reduced by farnesol. Med. Mycol. 51, 53–59.

    Article  CAS  PubMed  Google Scholar 

  • De Cremer, K., Staes, I., Delattin, N., Cammue, B.P., Thevissen, K., and De Brucker, K. 2015. Combinatorial drug approaches to tackle Candida albicans biofilms. Expert Rev. Anti Infect. Ther. 13, 973–984.

    Article  PubMed  Google Scholar 

  • Elizondo-Zertuche, M., Robledo-Leal, E., González, J.G., Ceceñas, L.A., and González, G.M. 2015. Efficacy of ravuconazole in a murine model of vaginitis by Candida albicans. Rev. Iberoam. Micol. 32, 30–33.

    Article  PubMed  Google Scholar 

  • Fidel, P.L.Jr., Cutright, J., and Steele, C. 2000. Effects of reproductive hormones on experimental vaginal candidiasis. Infect. Immun. 68, 651–657.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ganguly, S. and Mitchell, A.P. 2011. Mucosal biofilms of Candida albicans. Curr. Opin. Microbiol. 14, 380–385.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • González, G.M., Robledo, E., Saldívar, D., González, G., Bosques, F., and Garza, E. 2007. Therapeutic efficacy of posaconazole against isolates of Candida albicans with different susceptibilities to fluconazole in a vaginal model. Med. Mycol. 45, 221–224.

    Article  PubMed  Google Scholar 

  • Han, T.L., Cannon, R.D., and Villas-Bôas, S.G. 2012. The metabolic response of Candida albicans to farnesol under hyphae-inducing conditions. FEMS Yeast Res. 12, 879–889.

    Article  CAS  PubMed  Google Scholar 

  • Harriott, M.M., Lilly, E.A., Rodriguez, T.E., Fidel, P.L.Jr., and Noverr, M.C. 2010. Candida albicans forms biofilms on the vaginal mucosa. Microbiology 156, 3635–3644.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hawser, S. 1996. Comparisons of the susceptibilities of planktonic and adherent Candida albicans to antifungal agents: a modified XTT tetrazolium assay using synchronised C. albicans cells. J. Med. Vet. Mycol. 34, 149–152.

    Article  CAS  PubMed  Google Scholar 

  • Hisajima, T., Maruyama, N., Tanabe, Y., Ishibashi, H., Yamada, T., Makimura, K., Nishiyama, Y., Funakoshi, K., Oshima, H., and Abe, S. 2008. Protective effects of farnesol against oral candidiasis in mice. Microbiol. Immunol. 52, 327–333.

    Article  CAS  PubMed  Google Scholar 

  • Hornby, J.M., Jensen, E.C., Lisec, A.D., Tasto, J.J., Jahnke, B., Shoemaker, R., Dussault, P., and Nickerson, K.W. 2001. Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl. Environ. Microbiol. 67, 2982–2992.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hornby, J.M. and Nickerson, K.W. 2004. Enhanced production of farnesol by Candida albicans treated with four azoles. Antimicrob. Agents Chemother. 48, 2305–2307.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jabra-Rizk, M.A., Shirtliff, M., James, C., and Meiller, T. 2006. Effect of farnesol on Candida dubliniensis biofilm formation and fluconazole resistance. FEMS Yeast Res. 6, 1063–1073.

    Article  CAS  PubMed  Google Scholar 

  • Katragkou, A., McCarthy, M., Alexander, E.L., Antachopoulos, C., Meletiadis, J., Jabra-Rizk, M.A., Petraitis, V., Roilides, E., and Walsh, T.J. 2015. In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against Candida albicans biofilms. J. Antimicrob. Chemother. 70, 470–478.

    Article  CAS  PubMed  Google Scholar 

  • Kovács, R., Bozó, A., Gesztelyi, R., Domán, M., Kardos, G., Nagy, F., Tóth, Z., Majoros, L. 2016. Effect of caspofungin and micafungin in combination with farnesol against Candida parapsilosis biofilms. Int. J. Antimicrob. Agents 47, 304–310.

    Article  PubMed  Google Scholar 

  • Kovács, R., Czudar, A., Horváth, L., Szakács, L., Majoros, L., and Kónya, J. 2014. Serum interleukin-6 levels in murine models of Candida albicans infection. Acta Microbiol. Immunol. Hung. 61, 61–69.

    Article  PubMed  Google Scholar 

  • Langford, M.L., Atkin, A.L., and Nickerson, K.W. 2009. Cellular interactions of farnesol, a quorum-sensing molecule produced by Candida albicans. Future Microbiol. 4, 1353–1362.

    Article  CAS  PubMed  Google Scholar 

  • Louie, A., Banerjee, P., Drusano, G.L., Shayegani, M., and Miller, M.H. 1999. Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or-resistant strains of Candida albicans. Antimicrob. Agents Chemother. 43, 2841–2847.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Martins, M., Lazzell, A.L., Lopez-Ribot, J.L., Henriques, M., and Oliveira, R. 2012. Effect of exogenous administration of Candida albicans autoregulatory alcohols in a murine model of hematogenously disseminated candidiasis. J. Basic Microbiol. 52, 487–491.

    Article  CAS  PubMed  Google Scholar 

  • Meletiadis, J., Verweij, P.E., TeDorsthorst, D.T., Meis, J.F., and Mouton, J.W. 2005. Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. Med. Mycol. 43, 133–152.

    Article  CAS  PubMed  Google Scholar 

  • Navarathna, D.H., Hornby, J.M., Krishnan, N., Parkhurst, A., Duhamel, G.E., and Nickerson, K.W. 2007. Effect of farnesol on a mouse model of systemic candidiasis, determined by use of a DPP3 knockout mutant of Candida albicans. Infect. Immun. 75, 1609–1618.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • O’Toole, G.A. 2011. Microtiter dish biofilm formation assay. J. Vis. Exp. 47, pii: 2437.

    Google Scholar 

  • Pfaller, M.A., Andes, D., Diekema, D.J., Espinel-Ingroff, A., Sheehan, D., and CLSI Subcommittee for Antifungal Susceptibility Testing. 2010. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 13, 180–195.

    Article  CAS  PubMed  Google Scholar 

  • Pierce, C.G., Srinivasan, A., Uppuluri, P., Ramasubramanian, A.K., and López-Ribot, J.L. 2013. Antifungal therapy with an emphasis on biofilms. Curr. Opin. Pharmacol. 13, 726–730.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pierce, C.G., Uppuluri, P., Tristan, A.R., Wormley, F.L.Jr., Mowat, E., Ramage, G., and Lopez-Ribot, J.L. 2008. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat. Protoc. 3, 1494–1500.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ramage, G., Saville, S.P., Wickes, B.L., and López-Ribot, J.L. 2002. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl. Environ. Microbiol. 68, 5459–5463.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sharma, M. and Prasad, R. 2011. The quorum-sensing molecule farnesol is a modulator of drug efflux mediated by ABC multidrug transporters and synergizes with drugs in Candida albicans. Antimicrob. Agents Chemother. 55, 4834–4843.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Uppuluri, P., Chaturvedi, A.K., Srinivasan, A., Banerjee, M., Ramasubramaniam, A.K., Köhler, J.R., Kadosh, D., and Lopez-Ribot, J.L. 2010. Dispersion as an important step in the Candida albicans biofilm developmental cycle. PLoS Pathog. 6, e1000828.

    Article  Google Scholar 

  • Zhou, Y., Wang, G., Li, Y., Liu, Y., Song, Y., Zheng, W., Zhang, N., Hu, X., Yan, S., and Jia J. 2012. In vitro interactions between aspirin and amphotericin B against planktonic cells and biofilm cells of Candida albicans and C. parapsilosis. Antimicrob. Agents Chemother. 56, 3250–3260.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Microbiology, Faculty of Medicine, University of Debrecen, Debrecen, 4032, Hungary

    Aliz Bozó, Marianna Domán, László Majoros, Gábor Kardos & Renátó Kovács

  2. Department of Periodontology, Faculty of Dentistry, University of Debrecen, Debrecen, 4032, Hungary

    István Varga

Authors
  1. Aliz Bozó
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marianna Domán
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. László Majoros
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gábor Kardos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. István Varga
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Renátó Kovács
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Renátó Kovács.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bozó, A., Domán, M., Majoros, L. et al. The in vitro and in vivo efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a murine vulvovaginitis model. J Microbiol. 54, 753–760 (2016). https://doi.org/10.1007/s12275-016-6298-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12275-016-6298-y

Keywords

Search

Navigation